Iterum Therapeutics to Present in Upcoming Investor Conferences
February 19 2021 - 5:30PM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that Corey Fishman, Chief Executive
Officer, will provide a company overview and business update at the
following upcoming investor conferences:
- SVB Leerink Annual
Global Healthcare Conference: Thursday, February 25,
2021 at 3:00 pm ET
- HC Wainwright Global
Life Sciences Conference: on-demand beginning at 7:00 am
ET on March 9, 2021
The company presentation may also be accessed by visiting the
“Investors” section of the Company’s website under the “Events and
Presentations” tab at www.iterumtx.com.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation and IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum Therapeutics has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications.
Forward-Looking Statements
This press release contains forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding the development, therapeutic and
market potential of sulopenem. In some cases, forward-looking
statements can be identified by words such as “may,” “believes,”
“intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,”
“should,” “assumes,” “continues,” “could,” “would,” “will,”
“future,” “potential” or the negative of these or similar terms and
phrases. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the Company’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements include all matters that are not
historical facts. Actual future results may be materially different
from what is expected due to factors largely outside the Company’s
control, including the uncertainties inherent in the initiation and
conduct of clinical trials, availability and timing of data from
clinical trials, changes in regulatory requirements or decisions of
regulatory authorities, the timing of approval of any submission,
changes in public policy or legislation, commercialization plans
and timelines, if oral sulopenem is approved, the actions of
third-party clinical research organizations, suppliers and
manufacturers, risks regarding intellectual property rights in
product candidates and the ability to defend and enforce any such
intellectual property rights, the accuracy of the Company’s
expectations regarding how far into the future the Company’s cash
on hand will fund the Company’s ongoing operations, the impact of
COVID-19 and related responsive measures thereto, the outcome,
impact, effects and results of the Company’s evaluation of
corporate, organizational, strategic, financial and financing
alternatives, including the terms, timing, structure, value,
benefits and costs of any corporate, organizational, strategic,
financial or financing alternative and the Company’s ability to
complete one at all and other factors discussed under the caption
“Risk Factors” in its most recently filed Quarterly Report on Form
10-Q, and other documents filed with the SEC from time to time.
Forward-looking statements represent the Company’s beliefs and
assumptions only as of the date of this press release. Except as
required by law, the Company assumes no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
Investor Contact:Judy
MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2023 to Aug 2024